AIDS 2010
AIDS 2010: Early Antiretroviral Therapy during Tuberculosis Treatment Improves Survival
- Details
- Category: HIV Treatment
- Published on Friday, 30 July 2010 13:56
- Written by Liz Highleyman
Starting antiretroviral therapy (ART) 2 weeks rather than 2 months after beginning tuberculosis (TB) treatment led to longer survival for HIV positive people with severe immune deficiency in the CAMELIA study, researchers reported at the XVIII International AIDS Conference (AIDS 2010) last week in Vienna. Cambodian patients receiving early ART were more likely to develop immune reconstitution inflammatory syndrome (IRIS), but this was generally manageable and starting sooner reduced mortality by more than 30%.
AIDS 2010: Studies Explore NRTI-sparing Antiretroviral Regimens Using New Drug Classes
- Details
- Category: HIV Treatment
- Published on Friday, 30 July 2010 13:56
- Written by Liz Highleyman
Novel antiretroviral therapy (ART) regimens that combine boosted protease inhibitors with a new integrase inhibitor or CCR5 antagonist, while omitting nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), demonstrated good efficacy and tolerability in treatment-naive patients, researchers reported at the XVIII International AIDS Conference last week in Vienna. A regimen containing unboosted atazanavir plus raltegravir, however, raised concerns about side effects and drug resistance.
AIDS 2010: Does Nevirapine Improve Response to Interferon-based Therapy in HIV/HCV Coinfected Patients?
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 27 July 2010 13:56
- Written by Liz Highleyman
Use of an antiretroviral therapy (ART) regimen containing nevirapine (Viramune) was associated with a higher rate of sustained virological response (SVR) to interferon-based therapy among HIV/HCV coinfected patients, according to a study presented last week at the XVIII International AIDS Conference (AIDS 2010) in Vienna. Researchers suggested that nevirapine may improve treatment response by reducing hepatitis C virus (HCV) viral load, but an alternative explanation may be that people taking nevirapine are in better health when starting hepatitis C treatment.
AIDS 2010: Oral Tenofovir for Pre-exposure Prophylaxis Appears Safe and Does Not Discourage Safer Sex
- Details
- Category: HIV Prevention
- Published on Friday, 30 July 2010 13:56
- Written by Liz Highleyman
HIV pre-exposure prophylaxis (PrEP) using once-daily oral tenofovir appeared safe and did not increase the likelihood of risky sexual behavior among men who have sex with men in 3 U.S. cities, researchers reported in a late-breaker presentation at the XVIII International Conference on AIDS (AIDS 2010) last week in Vienna. The study found no indication of significant safety issues including kidney problems or bone loss. None of the 7 men who became HIV infected during the 2-year follow-up period were taking tenofovir, but this analysis was not powered to determine effectiveness.
AIDS 2010: Early Antiretroviral Treatment Reduces New HIV Infections, Says British Columbia Study
- Details
- Category: Treatment as Prevention
- Published on Friday, 23 July 2010 13:56
- Written by HIVandHepatitis.com
A study published in the July 18, 2010 advance online edition of the Lancet (free full text with registration) and discussed at the XVIII International AIDS Conference (AIDS 2010) this week in Vienna offers further evidence that widespread early antiretroviral therapy (ART) can reduce the spread of HIV at a population level. Universal early ART is not without controversy, however, due to concerns about side effects, drug resistance, and resource allocation.
More Articles...
- AIDS 2010: NRTI-sparing Regimen of Lopinavir/ritonavir plus Raltegravir Works as Well as Traditional 3-drug HAART
- More Promising Data on GSK572 Integrase Inhibitor, Phase 3 Studies to Begin Soon
- AIDS 2010: CDC Study Reveals High HIV Infection Rates Linked to Poverty More than Race
- IAPAC Survey Finds Gaps in Patient-Physician Conversations Affect Treatment Outcomes
Web Design and Development by